Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

Debt instruments come in different forms, some more obvious than others. Keep reading to find out more about debt instruments and the most common types issued by lenders. A debt instrument is an ...

Eli Lilly’s acquisition of gene therapy specialist Akouos seems to have paid off, after the lead candidate in the deal restored hearing in a child with congenital deafness. The AK-OTOF therapy ...